Fighting Cancer

Every Step of the Way

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit
vb-homepage-image3

Dedicated to Early Intervention. And Life.


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Its OncAlert™ Oral Cancer Risk Assessment System uses patented technology that is highly-accurate and specific.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences’ products are based on patented technology that detects specific protein markers known to clinically show elevated risk for early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or Lab

Both the rapid point-of-care test and the lab assay that comprise the OncAlert™ system provide a timely, accurate, and specific risk assessment for oral cancer... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • dentistry-today

    Personal Journey Drives Cancer Innovation

    Today’s oral cancer detection products typically rely on revealing abnormalities or detecting HPV. Yet these tests aren’t necessarily accurate or timely, discovering dangers sometimes long after they are underway. Driven by a passion for science and personal challenges, Matthew Kim…more

  • dentistry-today

    Companies Ink Deal for Oral Cancer Detection Products

    Vigilant Biosciences has struck a three-year deal with Crown Dental + Medical Limited to distribute the OncAlert Oral Cancer Risk Assessment System in New Zealand. The product includes the OncAlert Oral Cancer Rapid Point-of-Care Risk Assessment Test (OncAlert POC Test)…more

  • vb-400x210

    Vigilant Biosciences Announces Agreement with Crown Dental + Medical Limited for Exclusive Distribution of the OncAlert™ Oral Cancer Risk Assessment System in New Zealand

    AUCKLAND, New Zealand and FORT LAUDERDALE, Fla., Aug. 18, 2015 /PRNewswire/ — NZDA Conference, Booth 60-61 – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that…more

  • mlo_logo

    Special Feature: Saliva as a diagnostic tool

    By Elizabeth Franzmann, MD, July 2015 Salivary diagnostics holds tremendous potential for the diagnosis, prognosis, and monitoring of cancer.1 The specimen can be obtained simply, inexpensively, and less invasively than blood and thus can be collected without special training.1-3 Saliva…more


©2011-2015 Vigilant Biosciences, Inc. All Rights Reserved.

×